Drug Trial Radar · NCT03622580
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
940
Actual
Start
Sep 5, 2018
Primary completion
Oct 20, 2020
Study completion Sep 3, 2021
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Conditions
- Diabetic Macular Edema
Interventions
AfliberceptDrug
Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
FaricimabDrug
Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
Sham ProcedureProcedure
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive PopulationsTime frame: From Baseline through Week 56
Locations
185 sites in 16 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Retina Associates Southwest PC
Tucson, Arizona
Retinal Diagnostic Center
Campbell, California
Eye Medical Center
Fresno, California
East Bay Retina Consultants
Oakland, California
Southern CA Desert Retina Cons
Palm Desert, California
California Eye Specialists Medical group Inc.
Pasadena, California
Retina Consultants, San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
Kaiser Permanente Riverside Medical Center
Riverside, California
University of California, Davis, Eye Center
Sacramento, California
W Coast Retina Med Group Inc
San Francisco, California
Orange County Retina Med Group
Santa Ana, California
Colorado Retina Associates, PC
Lakewood, Colorado
Rand Eye
Deerfield Beach, Florida
Retina Care Specialists
Palm Beach Gardens, Florida
Retina Specialty Institute
Pensacola, Florida
Southern Vitreoretinal Assoc
Tallahassee, Florida
Retina Associates of Florida, LLC
Tampa, Florida
University of South Florida
Tampa, Florida
Georgia Retina PC
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Midwest Eye Institute
Indianapolis, Indiana
Wolfe Eye Clinic
West Des Moines, Iowa
Retina Associates
Lenexa, Kansas
Vitreo-Retinal Consultants
Wichita, Kansas
Retina Associates of Kentucky
Lexington, Kentucky
Paducah Retinal Center
Paducah, Kentucky
Maine Eye Center
Portland, Maine
The Retina Care Center
Baltimore, Maryland
Johns Hopkins Med; Wilmer Eye Inst
Baltimore, Maryland
Retina Group of Washington
Chevy Chase, Maryland
Cumberland Valley Retina PC
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Beetham Eye Institute, Joslin Diabetes Center
Boston, Massachusetts
Vitreo-Retinal Associates, PC
Worcester, Massachusetts
Foundation for Vision Research
Grand Rapids, Michigan
Assoc Retinal Consultants PC
Royal Oak, Michigan
Associated Retinal Consultants, P.C.
Traverse City, Michigan
Showing 40 of 185 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.